Open tender · Belgium · Various medicinal products
infliximab IV - tocilizumab IV en SC - natalizumab IV - denosumab SC
In EnglishInfliximab IV - Tocilizumab IV and SC - Natalizumab IV - Denosumab SC
Emmaus VZW in Belgium is inviting bids for “Infliximab IV - Tocilizumab IV and SC - Natalizumab IV - Denosumab SC”. Bids close on 13 October 2026, 08:00 CEST; the estimated value is €3.25 million (framework maximum). askTender lists every requirement to qualify and checks whether your company meets them.
The tender in brief
Supply of four biologic medicines (infliximab, tocilizumab, natalizumab, denosumab) to a Belgian care provider
A Belgian organisation, Emmaus, is buying four biologic medicines: infliximab 100 mg intravenous vials, tocilizumab (intravenous and subcutaneous), natalizumab 300 mg intravenous vials, and denosumab 120 mg pre-filled subcutaneous syringes. The contract is awarded on price and sustainability.
Key facts
- Framework maximum
- €3.25 million
- Procedure
- Contract notice
- How bids are judged
- Awarded on price and sustainability
Before you bid, askTender
Everything else is in your askTender account
The requirements to qualify, the eligibility check and the bid documents for this tender are in your askTender account.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences